NCT01983657UNKNOWNanonymous

Study of Subcutaneous Injection of Low-dose Recombinant Granulocyte Macrophage-Colony Stimulating Factor (rhGM-CSF) +/- Whole Lung Lavage(WLL) in Pulmonary Alveolar Proteinosis.

Sponsor

Source record

Shanghai Pulmonary Hospital, Shanghai, China

Phase

Source record

PHASE2

Modality

AI-normalized

small molecule

Target

AI-normalized

rhGM-CSF, Whole Lung Lavage(WLL)

Indication / condition

AI-normalized

Pulmonary Alveolar Proteinosis

Intervention

Source record

rhGM-CSF, Whole Lung Lavage(WLL)

Related intelligence directories

Indication directory: Pulmonary Alveolar Proteinosis Modality directory: small molecule Target directory: rhGM-CSF

Source & freshness

Source record

NCT ID

NCT01983657

Original source

ClinicalTrials.gov

Source last updated

Nov 18, 2013

Ingested at

May 21, 2026

Internal sync

May 23, 2026

Model version

trialsignal-ai-v1

Normalized confidence

96%

Validation status

validated

Open original registry record

View original source fields

NCT ID

NCT01983657

Title

Study of Subcutaneous Injection of Low-dose Recombinant Granulocyte Macrophage-Colony Stimulating Factor (rhGM-CSF) +/- Whole Lung Lavage(WLL) in Pulmonary Alveolar Proteinosis.

Sponsor

Shanghai Pulmonary Hospital, Shanghai, China

Status

UNKNOWN

Phase

PHASE2

Condition raw

Pulmonary Alveolar Proteinosis

Condition normalized

Pulmonary Alveolar Proteinosis

Modality raw

small molecule

Modality normalized

small molecule

Target raw

rhGM-CSF, Whole Lung Lavage(WLL)

Target normalized

rhGM-CSF, Whole Lung Lavage(WLL)

Interventions

rhGM-CSF, Whole Lung Lavage(WLL)

Public preview

Source record

The purpose of this study is to establish an efficient and economic treatment scheme by evaluation of the safety and efficacy of subcutaneous injection of low-dose rhGM-CSF, or of similar injection after whole lung lavage , in patients with PAP.

AI-generated analysis supports research triage only. Verify source records, publications, sponsor disclosures and IP databases before making diligence decisions. Model: trialsignal-ai-v1.

Report access

Create an account to unlock this report

Choose the access model that matches the job: one urgent report, reusable credits for project work, or unlimited monthly access with AI and folders.

Early access offer

Subscribe with code FOUNDERS5 for a 5-day premium trial.

Full protocol, outcomes, eligibility, contacts and results sections

Patent/IP landscape with verified records when available

Board-ready PDF export with source provenance

Save to folders and synthesize multiple assets in premium workspace

Create account

Create a free account first, then unlock a single report, buy credits or subscribe.

TrialSignal

Clinical trial intelligence report

Study of Subcutaneous Injection of Low-dose Recombinant Granulocyte Macrophage-Colony Stimulating Factor (rhGM-CSF) +/- Whole Lung Lavage(WLL) in Pulmonary Alveolar Proteinosis.

Source-linked diligence brief with registry provenance, taxonomy normalization and premium analytical context.

Generated

Jun 20, 2026

NCT ID

NCT01983657

Status

UNKNOWN

Phase

PHASE2

Sponsor

Shanghai Pulmonary Hospital, Shanghai, China

Executive brief

Investment-Ready Snapshot

Source & freshness

Provenance

SourceClinicalTrials.gov

Source updatedNov 18, 2013

Internal syncMay 23, 2026

Model versiontrialsignal-ai-v1

https://clinicaltrials.gov/study/NCT01983657

Indication

Pulmonary Alveolar Proteinosis

Modality

small molecule

Target

rhGM-CSF, Whole Lung Lavage(WLL)

Intervention

rhGM-CSF, Whole Lung Lavage(WLL)

Source record

Protocol Description

Detailed source ingestion pending.

Source record

Outcome Measures

Detailed source ingestion pending.

Source record

Eligibility

Detailed source ingestion pending.

AI analysis

Known Results And Readout Context

Detailed source ingestion pending.

IP intelligence

Patent And IP Landscape

Detailed source ingestion pending.

Source record

Contacts

Detailed source ingestion pending.